For German life-sciences companies reducing their concentration in one large Asian market, ASEAN is the obvious hedge — young, growing, and politically neutral. But it is not one market. It is ten regulators wearing a shared label, and in most of them your product licence is held by somebody else.
ASEAN is harmonising medical-device rules through the ASEAN Medical Device Directive (AMDD) — a shared risk-based classification and a Common Submission Dossier Template (CSDT) — but adoption is uneven, and registration remains national. In nearly every market a foreign manufacturer must appoint a licensed local representative, and in some the representative holds your product licence. Add a separate procurement layer (Indonesia's e-Katalog, Vietnam's new tender classification) and the pattern is familiar: licensed isn't distributed, and listed isn't bought.
The single biggest planning error is treating ASEAN as a market. It is a region with a shared vocabulary and ten separate front doors.
The attraction is real: a large, young population, fast-growing healthcare spending, policy support for manufacturing, and a position that many boards now value precisely because it is not concentrated exposure to one giant. That is why Southeast Asia has become the default first step in diversifying an Asia strategy rather than the afterthought it once was.
What it does not offer is a single approval. The ASEAN Medical Device Committee (AMDC), formed in 2014, coordinates the AMDD across the ten member states — but a device approved in Malaysia is not thereby approved in Vietnam. Harmonisation has standardised the paperwork and the language, not the decision.
ASEAN harmonised the dossier. It did not harmonise the door. You still knock ten times.
Singapore is where most German companies base the region — and where AMDD adoption is furthest along. It is a headquarters, not a shortcut: each market below still requires its own registration and its own licensed representative.
Singapore, Malaysia and Indonesia are at the most advanced stage of AMDD compliance; the Philippines, Thailand and Cambodia have revised national rules toward it with further changes still to come.
Understanding the boundary of harmonisation is what separates a realistic ASEAN plan from an optimistic one.
Harmonised: a common risk-based classification for medical devices and IVDs, and the CSDT (Common Submission Dossier Template) — so the technical file you build for one member state is largely reusable in the next. That is a genuine saving in preparation effort.
Not harmonised: the approval itself, the timelines, the fees, the language requirements, the local-representation rules and — crucially — reimbursement and procurement. There is no ASEAN-wide marketing authorisation and no mutual recognition of national approvals.
Adoption also runs at different speeds. Singapore, Malaysia and Indonesia are furthest along; the Philippines, Thailand and Cambodia have amended national regulation toward AMDD with more to follow. Plan for the country you are entering, not for the directive.
This is the load-bearing requirement across the region. A German manufacturer without a local legal entity cannot register on its own — it must appoint a licensed local party. What that party is called, and what it controls, differs by country.
| Market | Who must be appointed | What to watch |
|---|---|---|
| Indonesia | Local Authorized Representative — an Indonesian legal entity holding a distributor licence (IDAK); it holds the product licence. | One device may be registered by only one licence holder; transfers and parallel registrations are not permitted. |
| Malaysia | A licensed establishment under the Medical Device Act 2012 — authorised representative, importer or distributor. | Only a licensed establishment may import, manufacture or distribute a registered device. |
| Thailand | A local registrant holding a Thai FDA Establishment Licence; often a neutral third-party legal representative. | Using an independent agent as legal representative makes changing distributors far easier later. |
| Vietnam | Local registration holder / authorised representative under the Decree 98 framework, as amended by Decree 04/2025. | Classification, dossier and post-market duties were refined effective 2025 — check the current version. |
| Singapore | A local registrant licensed by the HSA. | Most mature system; commonly used as the regional base rather than the first revenue market. |
The same logic you know from Germany applies here, mirrored: the representative is a legal role with real responsibility, not an administrative convenience. See local representation for the inbound equivalent.
In several ASEAN markets the local representative is also the holder of the product licence. Indonesia is the sharpest case: a device may be registered by only one licence holder, and licences are not transferable between them. If that holder is your distributor and the relationship sours, you do not simply switch partners — you may have to start the registration again, with the clock and the cost that implies.
The defence is structural and cheap if you do it first: appoint a neutral local representative or your own entity as the registration holder, and contract distribution separately. Thailand's practice of using an independent legal representative exists precisely for this reason.
Registration makes you legal. A separate, national procurement system decides whether you are bought.
Approved, listed, and bought are three different events. Budget for all three.
A workable order for a German manufacturer treating ASEAN as a diversification move rather than a scatter-gun.
Choose on reimbursement and procurement outlook, not population. Two done properly beats six half-registered.
Singapore as regional HQ and evidence hub, or run lean from Germany at first — a cost and control decision.
Decide who holds the registration before you sign any distributor. This is the one choice that is expensive to reverse.
Prepare the technical file to the common template so it is reusable across member states.
Catalogue listing, tender qualification and local partners — the layer that turns approval into orders.
Start with a fixed, written deliverable for your target markets, then plan execution in a working session — the same model we use on every corridor.
A one-off written roadmap for your ASEAN priority markets — before you appoint anyone or sign anything.
A focused session to pressure-test the plan, weigh a Singapore base against a lean start, and structure the partner relationship.